<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01886443</url>
  </required_header>
  <id_info>
    <org_study_id>CAPITL safety</org_study_id>
    <nct_id>NCT01886443</nct_id>
  </id_info>
  <brief_title>Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers</brief_title>
  <acronym>CAPITL</acronym>
  <official_title>Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL): a First-in-men Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the safety of the combined drug approach
      (anti-thrombin III, infliximab, apotransferrin, human recombinant erythropoietin beta,
      C1-inhibitor, glutathione, alfa-tocopherol, melatonin and epoprostenol)aimed to reduce
      ischemia-reperfusion injury during liver transplantation in eligible recipients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>During and within the 7 days following the liver transplantation</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>Combined drug approach, safety study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antithrombin-III</intervention_name>
    <arm_group_label>Combined drug approach, safety study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <arm_group_label>Combined drug approach, safety study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apotransferrin</intervention_name>
    <arm_group_label>Combined drug approach, safety study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human recombinant erythropoietin</intervention_name>
    <arm_group_label>Combined drug approach, safety study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C1-Inhibitor</intervention_name>
    <arm_group_label>Combined drug approach, safety study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glutathione</intervention_name>
    <arm_group_label>Combined drug approach, safety study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfa-tocopherol</intervention_name>
    <arm_group_label>Combined drug approach, safety study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <arm_group_label>Combined drug approach, safety study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoprostenol</intervention_name>
    <arm_group_label>Combined drug approach, safety study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients suffering from irreversible liver failure eligible for liver transplantation
             according to Eurotransplant guidelines.

          2. Patients &gt; 18 years of age at time of listing on Eurotransplant waiting list for liver
             transplantation in University Hospitals Leuven, Belgium.

        Exclusion Criteria:

          1. Patients who refuse to participate in the study.

          2. History of hypersensitivity to one/several component(s) of the combined drug approach.

          3. Conditions that prevent the use of the combined drug approach:

               -  Administration of heparin at therapeutic dose pre-operatively,

               -  Congestive heart failure,

               -  Pre-operative level of hemoglobin higher than 13 mg/dl,

               -  History of seizure, poorly controlled arterial hypertension, myocardial
                  infarction or stroke in the month preceding the liver transplantation, venous
                  thromboembolic disease,

               -  Unstable angina pectoris,

               -  Sepsis, abcesses or opportunistic infections,

               -  History of infliximab treatment,

               -  Use of vitamin K antagonist anticoagulation.

          4. Mental conditions rendering the subject incapable to understand the nature, scope, and
             consequences of the trial.

          5. Combined organ transplantation.

          6. Re-transplantation.

          7. Patients that are dialysis-dependent prior to the liver transplantation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diethard Monbaliu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abdominal transplant surgery - transplant coordination, Abdominal transplant surgery lab (microbiology &amp; immunology Dpt)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Monbaliu D, Vekemans K, Hoekstra H, Vaahtera L, Libbrecht L, Derveaux K, Parkkinen J, Liu Q, Heedfeld V, Wylin T, Deckx H, Zeegers M, Balligand E, Buurman W, van Pelt J, Porte RJ, Pirenne J. Multifactorial biological modulation of warm ischemia reperfusion injury in liver transplantation from non-heart-beating donors eliminates primary nonfunction and reduces bile salt toxicity. Ann Surg. 2009 Nov;250(5):808-17. doi: 10.1097/SLA.0b013e3181bdd787.</citation>
    <PMID>19826248</PMID>
  </reference>
  <reference>
    <citation>Vekemans K, Monbaliu D, Balligand E, Heedfeld V, Jochmans I, Pirenne J, van Pelt J. Improving the function of liver grafts exposed to warm ischemia by the Leuven drug protocol: exploring the molecular basis by microarray. Liver Transpl. 2012 Feb;18(2):206-18. doi: 10.1002/lt.22446.</citation>
    <PMID>21987442</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2013</study_first_submitted>
  <study_first_submitted_qc>June 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2013</study_first_posted>
  <last_update_submitted>September 24, 2014</last_update_submitted>
  <last_update_submitted_qc>September 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver</keyword>
  <keyword>Transplantation</keyword>
  <keyword>Ischemia-reperfusion</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Antithrombins</mesh_term>
    <mesh_term>Antithrombin III</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

